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A B S T R A C T 
Objectives: To review the outcome following 
simultaneous pancreas and kidney transplantation 
in patients with type 1 diabetes mellitus and end-
stage renal disease, as well as those with type 2 
diabetes mellitus, and to discuss the applicability of 
this treatment in this locality. 
Methods: A systematic literature review was 
performed by searching the PubMed and Elsevier 
databases. The search terms used were “simultaneous 
pancreas and kidney transplantation”, “diabetes”, 
“pancreas transplant” and “SPK”. Original and major 
review articles related to simultaneous pancreas 
and kidney transplantation were reviewed. Papers 
published in English after 1985 were included. 
Clinical outcomes following transplantation were 
extracted for comparison between different treatment 
methods. Outcomes of simultaneous pancreas and 
kidney transplant and other transplantation methods 
were identified and categorised into patient survival, 
graft survival, diabetic complications, and quality of 
life. Patient survivals and graft survivals were also 
compared.
Results: Currently available clinical evidence 
shows good outcomes for type 1 diabetes mellitus 
in terms of patient survival, graft survival, diabetic 
Simultaneous pancreas and kidney 
transplantation as the standard surgical 
treatment for diabetes mellitus patients with  
end-stage renal disease
Introduction
Simultaneous pancreas and kidney transplantation 
(SPK) has emerged as the worldwide standard for 
treatment of patients with end-stage renal disease 
(ESRD) resulting from type 1 diabetes mellitus 
(T1DM). Multiple studies have shown that SPK can 
significantly improve both their quality of life (QOL) 
and long-term survival. With the advances in surgical 
techniques, immunosuppression, management of 
graft rejection, and other related complications, SPK 
can now be performed successfully in the majority 
of patients, with the pancreatic graft survival 
rate comparable with those of kidney and liver 
transplants.1 It is currently the predominant type of 
pancreas transplantation for diabetic patients with 
ESRD.2 According to the International Pancreas 
Transplant Registry, among over 35 000 pancreas 
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transplantations reported by the end of 2010, 
approximately 75% were SPK, 18% were pancreas 
after kidney transplantation (PAK), and 7% were 
pancreas transplantation alone.2 The vast majority of 
SPK performed in various countries used grafts from 
cadavers, while living donor pancreas and/or kidney 
grafts were used only in a minority of cases. 
 In this review, we first discuss the effectiveness 
of SPK in improving the outcome for diabetic patients 
with ESRD in comparison with other transplant 
options including kidney transplant alone (KTA). In 
addition, we address the controversy about whether 
patients with type 2 diabetes mellitus (T2DM)–
associated ESRD, as with T1DM patients, should 
also receive SPK. This is followed by a discussion on 
the surgical risks, operative complications, future 
directions, and the application of this treatment 
REVIEW ARTICLE
complications, and quality of life. For type 2 diabetes 
mellitus, the efficacy and application of the procedure 
remain controversial but the outcomes are possibly 
comparable with those in type 1 diabetes mellitus.
Conclusions: Simultaneous pancreas and kidney 
transplantation is a technically demanding procedure 
that is associated with significant complications, and 
it should be regarded as a ‘last resort’ treatment in 
patients whose diabetic complications have become 
life-threatening or severely burdensome despite best 
efforts in maintaining good diabetic control through 
lifestyle modifications and medications.
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胰腎聯合移植作為糖尿病患者末期腎病的標準 
手術療法
陳倬銘、詹明鑫、梁家俊、唐智謙、王庭峰、梁嘉傑
目的：分析曾接受胰腎聯合移植的一型糖尿病末期腎病患者的結果，
以及此手術應用於二型糖尿病患者的臨床證據，並探討這技術在香港
的可行性。
方法：通過PubMed和Elsevier論文搜索引擎進行系統性搜索。用
以搜索文獻的關鍵詞為「胰腎聯合移植」(simultaneous pancreas 
and kidney transplantation)、「糖尿病」(diabetes)、「胰腺移植」
(pancreas transplant)和「SPK」。原創和較重要的回顧文章均被納入
研究範圍。所有囊括的文章均為1985年後以英文發表的論文。集中搜
集關於移植後的臨床結果來比較不同的治療方法。按胰腎聯合移植和
其他移植方法的臨床結果分為患者生存期、移植物存活期、糖尿病併
發症和生活質量，並比較患者生存期和移植物存活期 。
結果：至目前為止臨床試驗的證據顯示胰腎聯合移植於一型糖尿病方
面在患者生存期、移植物存活期、糖尿病併發症和生活質量均有良好
結果。至於二型糖尿病方面，雖然手術效用和其具體應用仍存在爭
議，但結果可能與一型糖尿病相若。
結論：胰腎聯合移植技術要求高，亦可能發生嚴重的併發症，因此應
經過仔細篩選，例如當糖尿病併發症已危及病人生命或無法使用藥物
和生理調節控制血糖水平的病人，才施以胰腎聯合移植作為「最後手
段」。
approach in this locality. We reviewed original 
and review articles related to SPK. PubMed and 
Elsevier databases were searched using the keywords 
“simultaneous pancreas and kidney transplantation”, 
“diabetes”, “pancreas transplant”, and “SPK”. Articles 
published in English since 1985 were included. 
Outcomes of type 1 diabetes with 
end-stage renal disease following 
simultaneous pancreas and 
kidney transplantation versus 
kidney transplant alone (living or 
deceased donor)
The outcomes of SPK can be assessed in terms of 
patient survival, graft survival, control of diabetic 
complications, and improvement in QOL. In the 
following, comparisons with KTA are made.
Patient survival
The most important parameter is patient survival. 
Lindahl et al3 reviewed 15 studies that compared the 
survival outcomes of SPK, living donor kidney alone 
(LDKA), and deceased donor kidney alone (DDKA). 
The authors included nine studies with short-term 
(up to 10 years) and six studies with long-term 
(beyond 10 years) follow-up (Table 14-19; one more 
latest short-term study in 2015 was included19). 
Overall, most large-scale studies agree that DDKA 
is inferior to SPK and LDKA. Nonetheless, whether 
SPK or LDKA achieves superior patient survival 
remains controversial. For short-term outcomes, the 
overall survival rate of SPK recipients has been shown 
TABLE 1.  Patient survival: summary of studies comparing different transplantation methods4-19
Study, year of publication No. of patients Patient survival*
Short-term Rayhill et al,8 2000 805 SPK = LDK > DDK
Ojo et al,9 2001 9516 SPK = LDK > DDK
Sutherland et al,10 2001 396 SPK = LDK = DDK
Bunnapradist et al,11 2003 6016 SPK = DDK
Reddy et al,12 2003 18 549 SPK = LDK > DDK
Waki and Terasaki,13 2006 1088 SPK = DDK
Young et al,4 2009 11 362 LDK > SPK = DDK
Weiss et al,14 2009 8281 SPK+P > LDK > SPK-P = DDK
Norman et al,15 2011 6282 SPK+P > SPK-P
Sung et al,19 2015 11 253 SPK > KTA
Long-term Becker et al,16 2000 642 SPK > LDK > DDK
Mohan et al,17 2003 101 SPK > DDK
Morath et al,18 2008 11 420 SPK > LDK > DDK
Sollinger et al,7 2009 2100 SPK > LDK > DDK
Morath et al,5 2010 15 118 SPK > LDK > DDK
Lindahl et al,6 2013 630 SPK > LDK > DDK
Abbreviations: DDK = deceased donor kidney; KTA = kidney transplant alone; LDK = living donor kidney; SPK = simultaneous 
pancreas and kidney transplantation; SPK+P = functioning pancreas graft at 1 year after transplant; SPK-P = no functioning pancreas 
graft at 1 year after transplant
* ‘>’ Denotes statistically significantly longer survival, and ‘=’ no statistically significant difference in survival
  #  Chan et al #
64 Hong Kong Med J  ⎥  Volume 22 Number 1  ⎥  February 2016  ⎥  www.hkmj.org
to be almost equivalent to that of LDKA recipients, 
except in one large-scale study by Young et al4 which 
yielded a better survival rate in LDKA patients 
after adjustment for high-risk characteristics in this 
group of patients. Consistent with other studies, the 
unadjusted overall patient survival was equivalent 
for SPK and LDKA. For long-term outcomes, SPK 
recipients had a higher survival rate than LDKA 
recipients. This may be because the additional 
beneficial effects of pancreas transplantation on 
glycaemic control need time to manifest. Morath 
et al5 postulated that, over time, SPK would provide 
greater survival benefits since the initially higher 
associated operational mortalities would later 
be compensated by improved glycaemic control 
that reduced death from diabetic complications, 
particularly in terms of cardiovascular death. This 
view is further supported by the fact that the major 
cause of death in all these patients is primarily 
cardiovascular disease (62%), followed by infection 
(16%), malignancy (8%), and other causes (14%).6 It 
also potentially explained why in Young et al’s study,4 
despite initial superior patient survival following 
LDKA compared with SPK (1-year survival of 
LDKA, SPK, and DDKA was 97%, 95%, and 93%, 
respectively), the results began to favour SPK by the 
end of the 72-month study period. 
Graft survival
The assessment of graft survival in SPK includes 
that of the kidney and the pancreas. For kidney graft 
survival, the review by Lindahl et al3 found similar 
short-term (up to 10 years) kidney graft survival rates 
following SPK and LDKA; graft survival after DDKA 
was inferior. Long-term results (>10 years) showed 
that DDKA was inferior to both SPK and LDKA, 
and most long-term studies agreed that SPK was 
equivalent to LDKA, with the exception of a study 
by Morath et al5 that showed SPK to be superior to 
LDKA. As such, the current view is that SPK is at 
least non-inferior to LDKA in terms of long-term 
kidney graft survival, even though most SPK in the 
literature reviewed were from cadaver donors (Table 
24-6,8,10-20).
 For pancreas graft survival, the results from 
SPK have improved significantly over the past 
years due to improved surgical techniques and 
immunosuppressive regimens.3 Surgical techniques 
have evolved from the use of pancreatic duct 
occlusion (1983-1987) to that of exocrine drainage 
into the urinary bladder (1988-1999), and later to 
that of direct drainage into the proximal jejunum 
(2000 onwards). With the latter, the mean pancreas 
graft survival rates after 1 and 5 years have been 
reported to be 87% and 75%, respectively.3
Diabetic complications
In the present context of transplantation therapy, 
the important complications of T1DM include 
diabetic nephropathy, diabetic neuropathy, and 
TABLE 2.  Kidney graft survival: summary of studies comparing different transplantation methods4-6,8,10-20
Study, year of publication No. of patients Patient survival*
Short-term Rayhill et al,8 2000 805 SPK = LDK > DDK
Sutherland et al,10 2001 396 SPK = LDK = DDK
Bunnapradist et al,11 2003 6016 SPK = DDK
Reddy et al,12 2003 18 549 SPK = LDK > DDK
Waki and Terasaki,13 2006 1088 SPK = DDK
Young et al,4 2009 11 362 LDK > SPK = DDK
Weiss et al,14 2009 8281 SPK+P > LDK > SPK-P = DDK
Norman et al,15 2011 6282 SPK+P > SPK-P
Sung et al,19 2015 11 253 SPK > KTA
Long-term Becker et al,16 2000 642 SPK = LDK > DDK
Mohan et al,17 2003 101 SPK = DDK
Israni et al,20 2005 8323 SPK > DDK
Morath et al,18 2008 11 420 SPK = LDK > DDK
Morath et al,5 2010 15 118 SPK > LDK > DDK
Lindahl et al,6 2013 630 SPK = LDK > DDK
Abbreviations: DDK = deceased donor kidney; KTA = kidney transplant alone; LDK = living donor kidney; SPK = simultaneous 
pancreas and kidney transplantation; SPK+P = functioning pancreas graft at 1 year after transplant; SPK-P = no functioning pancreas 
graft at 1 year after transplant
* ‘>’ Denotes statistically significantly longer survival, and ‘=’ no statistically significant difference in survival
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an increased risk of cardiovascular diseases. For 
diabetic nephropathy, several studies have included 
kidney biopsy in graft assessment following SPK, so 
as to capture the early diabetes-related changes that 
might otherwise take time to manifest clinically. The 
common diabetes-related changes under electron 
microscopy include thickening of the glomerular 
basement membrane (GBM) and an increase in 
mesangial volume. The study by Bohman et al21 
was the first to perform kidney biopsy in two SPK 
patients and six KTA patients. Diabetes-related 
changes were seen in five of the six KTA recipients 
but not in any of the SPK recipients. Wilczek et al22 
included a larger sample size (20 SPK vs 30 KTA) 
with a mean postoperative biopsy time of 1 to 6.8 
years. The associated changes under light and 
electron microscopy were significantly fewer in 
the SPK group than the KTA group. Bilous et al23 
biopsied 12 PAK patients before and at least 1.9 
years after the pancreas transplant, and found no 
glomerular disease progression. They also compared 
the 12 PAK with 13 KTA patients, and found lower 
mesangial volume in the PAK group. Although most 
studies showed that the outcomes would be better 
in patients with SPK relative to those with KTA, 
whether the pancreas graft can halt nephropathy 
progression remains controversial. Nyberg et al24 
biopsied 11 SPK patients 2 to 4 years postoperatively, 
and found a mean increase in GBM thickness when 
compared with normal controls. While recurrence 
of diabetic nephropathy is still possible in the long 
run, current evidence nonetheless supports that 
SPK can at least delay the progression of diabetic 
nephropathy in comparison with KTA.
 Apart from its effect on the kidney, a pancreas 
transplant in SPK may potentially improve other 
organ systems that can be affected by diabetes. 
Diabetic neuropathy is an example. Navarro et al25 
compared 115 pancreas recipients with 92 patients 
prescribed standard insulin therapy. Neurological 
status was assessed by clinical examination, nerve 
conduction studies, and autonomic function 
test. Results up to 10 years showed significant 
improvement in nerve conduction studies and 
slight improvement on clinical examination and 
autonomic index in the SPK group. We proposed 
that pancreas transplantation could potentially 
halt the progression of diabetic neuropathy and 
may even lead to a degree of neurological 
improvement.
 Besides microvascular complications, 
macrovascular complications are a major concern 
in diabetic patients. Cardiovascular diseases, in 
particular coronary artery disease, contribute to a 
significant portion of mortality in T1DM patients. 
Whether SPK can provide benefit in this respect has 
been studied. Jukema et al26 observed 32 SPK patients 
with 26 functioning pancreas grafts and six non-
functioning pancreas grafts. Glycaemic control was 
measured by blood glucose level, and the progression 
of diffuse and focal coronary atherosclerosis was 
assessed by coronary angiography. It was found 
that in the presence of a functioning pancreas graft, 
glycaemic control was better and progression of 
coronary atherosclerosis was slower. This might also 
correlate with a lower risk of cardiovascular death 
and explain why long-term survival in SPK patients 
is superior to that of KTA patients.
Quality of life 
In addition to survival benefit and reduced co-
morbidity, improvement in QOL may also represent 
an important consideration. A functioning pancreas 
graft can potentially free a patient from the need 
for self-administered insulin and achieve more 
stable blood glucose levels.27-29 These outcomes 
may be associated with improvement in QOL. To 
directly quantify such improvement, some studies 
have used validated health-related quality of life 
(HRQOL) questionnaires to evaluate treatment 
outcomes. The latest cohort study by Martins et 
al30 compared the HRQOL scores of 126 patients 
before and after SPK with a follow-up duration 
of around 5 years. There were improvements in 
all domains under the Gastrointestinal Quality of 
Life Index post-transplantation, with a significant 
visual analogue scale health state improvement 
from 38% to 84%.30 Assessment by another tool, the 
EuroQol-5 Dimension questionnaire, also showed 
improvement in physical function, psychological 
status, social function, gastro-intestinal complaints, 
burden of medical treatment as well as the rate 
of unemployment.30 The majority of available 
studies have focused mainly on comparison of 
pre-transplant and post-transplant scores, or on 
transplanted and non-transplanted patients. Few 
studies have compared QOL outcomes between 
patients undergoing SPK and KTA. Sureshkumar et 
al31 conducted a case-control study involving 27 SPK 
patients and 27 KTA patients. The authors concluded 
that SPK patients had a significantly better diabetes-
related QOL.
Considerations in type 1 versus 
type 2 diabetes mellitus
Indications (in type 1 versus type 2 diabetes 
mellitus)
The predominant indication for SPK is T1DM 
patients with ESRD and adequate cardiac reserve 
who have no opportunity for a living donor kidney 
transplantation.32 Currently, most centres will 
perform SPK mainly for T1DM, less commonly 
for T2DM patients. Nonetheless there has been 
pervasive controversy on whether the long-term 
outcomes of SPK in the two groups actually differ. 
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This has important implications in organ allocation 
as T2DM is much more prevalent than T1DM. 
Several factors have to be considered. First, there 
are differences in pathogenesis between the two 
conditions—T2DM is attributed to insulin resistance 
in addition to insulin secretion defect; in T1DM, 
the pathogenesis involves the auto-destruction of 
islet cells, causing absolute insulin deficiency. This 
would theoretically render pancreas transplantation 
less efficacious in T2DM. Second, there is as yet 
no consensus on the distinction between the two 
conditions. For example, C-peptide, which is used 
in patient selection for SPK between T1DM and 
T2DM patients, has been shown by some studies to 
be unreliable in determining the outcomes of SPK.33 
Third, it should be noted that there exists major 
differences between the two groups of diabetic 
patients that make meaningful comparison difficult. 
These include disproportionate sample sizes; the 
presence of confounders such as age, obesity, co-
morbidities; and duration and treatment of the 
underlying diabetes.
 Notwithstanding, there has been an increasing 
amount of evidence showing comparable results 
of SPK in selected T2DM and T1DM patients.34 
In a large study using the data obtained from the 
Organ Procurement and Transplant Network/
United Network for Organ Sharing (OPTN/UNOS) 
between 2000 and 2007, Sampaio et al35 showed no 
significant difference in 5-year survival rate between 
T1DM and T2DM recipients despite the fact that 
the latter group had a higher risk of death due to 
older age and longer pre-transplant dialysis time. In 
the same study, the 5-year pancreas graft survival in 
T2DM patients (69.8%) was comparable with that 
in T1DM patients (72.4%); an inferior 5-year kidney 
graft survival was found (77.8% vs 73.5%; P=0.007).35 
After adjusting for other potential risk factors (eg 
time on dialysis, obesity), however, diabetes type 
was not identified as an independent prognostic 
factor.35
 Concerning the role of C-peptide in defining 
T1DM and T2DM during patient selection, Stratta 
et al36 stratified 162 SPK recipients according to pre-
transplant C-peptide levels into C-peptide ‘positive’ 
(≥2.0 ng/mL; n=30) and C-peptide ‘negative’ (<2.0 
ng/mL; n=132) groups. With a mean follow-up 
duration of 5.6 years, the two groups showed no 
statistically significant differences in pancreas graft, 
kidney graft, or patient survival.36 In a similar study 
involving 80 SPK recipients, 10 were classified as 
T2DM and 70 as T1DM.37 On Cox regression survival 
analyses, no statistically significant difference in 
graft and patient survival was found between the 
two groups.37 The authors concluded that selected 
T2DM patients with ESRD should be considered 
potential candidates for SPK, and that the use of C-
peptide as the predominant marker of the diabetes 
type was unreliable and potentially misleading.37
Simultaneous pancreas and kidney 
transplantation versus other transplant 
options in type 2 diabetes mellitus patients
At present, there is insufficient evidence to support 
the use of SPK over other kidney transplant options 
in patients with T2DM. In an early study that 
compared the outcomes of SPK, DDKA, and LDKA 
in patients with T2DM, Wiseman and Gralla38 
concluded that both patient and graft survival 
rates were superior with LDKA transplantation, 
whereas patient but not graft survival rate was 
higher in SPK versus DDKA transplantation. After 
multivariable analysis, the survival advantage of 
SPK over DDKA was related not so much to the 
pancreas transplantation but other variables such 
as younger donor and recipient ages in the SPK 
cohort (Table 338). These findings, however, should 
not completely dismiss the consideration of SPK for 
selected T2DM patients who have little prospect for 
LDKA since other outcome measures such as the 
TABLE 3.  Comparison of outcomes between simultaneous pancreas and kidney transplantation and living/deceased donor kidney 
alone by Wiseman and Gralla38
SPK Kidney transplantation P value
LDKA (n=424)  (n=1987)
Patient survival 82.0% 87.3% 0.003
Kidney survival 75.2% 81.2% 0.002
Death-censored kidney graft survival 86.2% 91.1% 0.003
DDKA (n=424) (n=4005)
Patient survival 82.0% 75.5% 0.04
Kidney survival 75.2% 65.1% 0.004
Death-censored kidney graft survival 86.2% 82.6% 0.21
Abbreviations: DDKA = deceased donor kidney alone; LDKA = living donor kidney alone; SPK = simultaneous pancreas and kidney 
transplantation
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benefits of euglycaemia in terms of better QOL and 
secondary complications of diabetes will also have to 
be considered. Nonetheless, given the superior long-
term outcome of SPK over LDKA in T1DM patients 
and that the same has yet to be demonstrated in 
T2DM patients, T1DM patients should still be given 
a stronger allocation priority of SPK grafts.3
Complications of simultaneous 
pancreas and kidney 
transplantation
Most complications of SPK are related to the 
transplanted pancreas.39 Repeated laparotomy 
may be required in up to 50% of patients.40,41 The 
pancreatic graft survival at 1 year may range from 
74% to 88%, with the sharpest drop during the 
first year.7,39,42 The reported 10-year and 20-year 
survival rates were 63% and 36%, respectively.7 
Most complications occur within the first 60 days 
of operation and include graft pancreatitis (3%-
12%), infection/abscess (1%-5%), focal/diffuse 
necrosis (12%), graft-vessel thrombosis (6%-17%), 
anastomotic leak (0.5%-2%), and intra-abdominal 
haemorrhage (0%-0.5%).39-43 Venous thrombosis has 
been reported to be the most common cause of graft 
failure; graft pancreatitis and focal/diffuse necrosis 
were the most common causes of mortality among 
graft-specific complications.39,40
 Complications related to the transplanted 
kidney include acute tubular necrosis (ATN) or 
graft rejection, urinary complications, infection, 
and vascular thrombosis. According to a study of 
112 SPK recipients by Grochowiecki et al,44 ATN 
and rejection were the most frequent (43.4%) 
causes leading to the loss of kidney graft function. 
Infections (28.6%) and vascular thrombosis due 
to atherosclerosis of the iliac arteries (28.6%) were 
the most common reasons for graft nephrectomy.44 
The most severe complications were due to fungal 
infection.44 Overall, the 1-year survival rate for the 
kidney graft was over 90%.7,44,45 The 10-year and 
20-year kidney survival rates were 63% and 38%, 
respectively.7 In terms of overall mortality, the most 
common causes following SPK have been reported 
to be cardiopulmonary (7.2%), followed by infection 
(3.4%), stroke (1.8%), and renal failure (1.5%). Patient 
survival rates at 1, 10, and 20 years were 97%, 80%, 
and 58%, respectively.7
 Comparison of the complications of SPK versus 
KTA has revealed that SPK has a lower rate of ATN 
(8.9%)44 than KTA (15.3%),46 but a slightly higher 
rate of urological complications (4.5%)44 than KTA 
(3.7%).47 The incidence of vascular complications 
was comparable in SPK (1.8%)44 and KTA (0.5%-
4%).48-50 As mentioned above, SPK has higher long-
term patient and kidney survival rates than LDKA/
DDKA.
Future directions and local 
applicability of simultaneous 
pancreas and kidney 
transplantation 
Simultaneous pancreas and kidney transplantation 
has become an established treatment for patients 
with T1DM complicated by ESRD. The results have, 
so far, been promising. Furthermore, apart from 
SPK, newer techniques including pancreatic islet 
cell transplantation, and different combinations of 
living and/or deceased donor pancreas, islet cell and 
kidney graft transplantation are being evaluated. 
Current research aims to extend these techniques, 
still predominantly SPK, to the treatment of T2DM, 
for which LDKA remains the first-line treatment 
option. In situations where LDKA is not available for 
T2DM patients, DDKA remains the next best option. 
Regarding the ethical issues about graft allocation, 
the allocation of DDKA is based on an allocation 
system that takes account of patient age and waiting 
time as well as the degree of human leukocyte 
antigen (HLA) matching between the potential 
donor and the recipient.51 Difficulties may arise, 
however, when a deceased donor with both kidney 
and a pancreas graft has become available. Should 
the priority for these grafts be given to a patient on 
the SPK waiting list or a non–diabetes-related ESRD 
patient on the DDKA waiting list? And should the 
priority of SPK be given to a T2DM patient who is 
higher up on the allocation system (with a younger 
age, a longer waiting time, or lesser degree of HLA 
mismatch) or to a T1DM patient who is lower on 
the allocation system but is more likely to achieve 
a better outcome? The related ethical issues clearly 
deserve an informed discourse within the surgical 
community.  
 Simultaneous pancreas and kidney 
transplantation has not yet been performed in this 
locality. The main obstacle remains the shortage 
of cadaver organs. Here, the number of cadaveric 
renal transplantations performed in the Hospital 
Authority over the last decade ranges from 44 to 87 
cases per year. As of 31 December 2014, the number 
of patients waiting for transplantation was close to 
2000. This translates into significantly prolonged 
dialysis time for this specific group of patients, and 
hence a potentially suboptimal outcome after SPK. 
The implementation of SPK would not be readily 
feasible unless there is a significant improvement in 
organ availability. 
Conclusions
Simultaneous pancreas and kidney transplantation 
has become a standard treatment worldwide for 
patients with T1DM and ESRD. There is a large 
volume of clinical evidence supporting good 
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outcomes in patient survival, graft survival, diabetic 
complications, and QOL. For T2DM, the efficacy and 
application of the procedure remain controversial 
but the outcomes are possibly comparable to that 
in T1DM. Simultaneous pancreas and kidney 
transplantation is a technically demanding 
procedure that is associated with significant 
complications, and should be undertaken only in 
carefully selected patients. It should be regarded 
as a ‘last resort’ treatment for patients in whom 
diabetic complications have become life-threatening 
or severely burdensome despite best efforts in 
maintaining good diabetic control through lifestyle 
modification and medications. Continued efforts in 
patient education and the promotion of an altruistic 
culture of organ donation among the public are 
critical for the implementation of this treatment 
paradigm in this locality.
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